

October 2019

TarGeting B-Cell Diseases

Forward Looking Safe Harbor Statement

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as "anticipates", "expects", "plans", "believes", "intends", and similar words or phrases. Such statements involve risks and uncertainties that could cause TG Therapeutics' actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in clinical trials, drug development, and commercialization. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and TG Therapeutics undertakes no obligation to update these statements, except as required by law.



TG is a biotechnology company focused on developing medicines for patients with Bcell diseases:



- Chronic Lymphocytic Leukemia
- Marginal Zone Lymphoma
- Follicular Lymphoma
- Diffuse Large B-Cell Lymphoma

Multiple Sclerosis

Autoimmune

- Myasthenia Gravis
- Rheumatoid Arthritis
- Lupus



Unique Approach to Drug Development


IDENTIFY



Identify validated targets for B-cell diseases

 Based on preclinical or clinical data known to be important in the treatment of B-cell disease


ACQUIRE



Search & Acquire "Best-in-Class" Compounds

 Compounds that have the potential to offer improvements over available therapies

DEVELOP



Develop Multi-drug Combinations

• To develop functional cures for cancers requires multiple drugs...*solutions development*



B-Cell Focused Platform *Clinical Stage Portfolio Overview*

Product	Mechanism of Action	Stage of Development
Umbralisib (TGR-1202)	ΡΙ3Κδ/CΚ1ε	Phase 3
Ublituximab (TG-1101)	Anti-CD20	Phase 3
TG-1501	Anti-PD-L1	Phase 1b
TG-1701	BTKi	Phase 1
TG-1801	Anti-CD47/CD19	Phase 1



Umbralisib: Investigational Targeted Therapy with "Best-in-Class" Potential

	LATE CLINICAL DEVELOPMENT	US REGULATORY SUBMISSION PLAN
Umbralisib	Marginal Zone Lymphoma	YE 2019
	CLL (in combo with Ublituximab)	1H2020
	Follicular Lymphoma	•
	Small Lymphocytic Lymphoma	

Next Generation PI3K delta inhibitor

Overcomes 1st generation Toxicity

Activity across NHL and CLL

Once daily oral dosing vs. BID or IV



First Generation PI3K-delta's are highly active but tolerability has limited market utilization

Idelalisib

Black-Box Warning⁽¹⁾

- Fatal and/or serious <u>hepatotoxicity</u> occurred in 16% -18% of Zydelig-treated patients
- Fatal and/or serious <u>diarrhea or</u> <u>colitis</u> occurred in 14% - 20% of Zydelig-treated patients
- Fatal and/or serious <u>pneumonitis</u> occurred in 4% of Zydelig-treated patients
- Fatal and/or serious infections occurred in 21% - 48% of patients treated with Zydelig monotherapy

Duvelisib

Black-Box Warning⁽²⁾

- Fatal and/or serious infections occurred in 31% of Copiktratreated patients
- Fatal and/or serious <u>diarrhea or</u> <u>colitis</u> occurred in 18% of Copiktra-treated patients
- Fatal and/or serious <u>cutaneous</u> <u>reactions</u> occurred in 5% of Copiktra-treated patients
- Fatal and/or serious <u>pneumonitis</u> occurred in 5% of Copiktra-treated patients


Copanlisib

Warnings and Precautions⁽³⁾

- <u>Infections:</u> Serious, including fatal, infections occurred in 19% of Aliqopa-treated patients
- Hyperglycemia: Grade 3 or 4
 hyperglycemia occurred in 41% of Aliqopa-treated patients
- <u>Hypertension:</u> Grade 3 hypertension occurred in 26% of Aliqopa-treated patients
- <u>Non-Infection Pneumonitis:</u> Occurred in 5% of Aliqopa-treated patients
- Severe Cutaneous Reactions: Grade 3 and 4 cutaneous reactions occurred in 2.8% and 0.6% of Aliqopa-treated patients, respectively

> Market is in need of a well tolerated PI3K-delta

Umbralisib: Selectivity



In-vitro kinase profiling – all compounds at $1\mu M$

- Umbralisib exhibits greater selectivity to PI3k-delta compared to other PI3K inhibitors
- Red circles indicate which kinase is being inhibited
- The larger the red circle, the stronger the relative inhibition of the kinase


TG Therapeutics

8

DiscoverX KINOMEscan Burris, et al., Lancet Oncology 2018

Umbralisib: Selectivity

Umbralisib




- PI3K associated immunemediated toxicities are thought to be related to impaired Tregs (Lampson et al., Blood 2016)
- Umbraliib uniquely inhibits CK1-epsilon, an important conduit which may play a role in Treg development and function
- Combination of CK1-epsilon targeting and lack of inhibition of PI3K gamma may prevent impairment of Tregs, explaining the improved tolerability profile observed for umbralisib.




Data Supporting Planned Umbralisib Filing In MZL Breakthrough Therapy Designation Granted

- MZL Trial met primary endpoint exceeding target 40% ORR
- Following Discussions with FDA Plan to Commence Rolling Submission around YE2019



MZL patients have few treatment options and no available cures

- Approximately 7,500 new cases per year, with ~3,000 relapsed patients needing treatment each year
- Second largest indolent form of NHL
- Affects mostly elderly individuals



- **Chemo-immunotherapy:** non-specific, toxic contraindicated in certain unfit elderly patients
- **R²:** recently approved Revlimid plus Rituxan– can cause severe neutropenia and rash; secondary malignancy risks
- **Ibrutinib:** accelerated approval less than half of patients respond; tolerability issues
- PI3K Delta inhibitors: none approved
- Need for highly active, well-tolerated treatment option for MZL

Umbralisib: Convenient oral daily dosing appears well tolerated with ~50% ORR in MZL

Ublituximab: Investigational Next Generation Anti-CD20 Monoclonal Antibody



Ublituximab

Glycoengineered for enhanced potency over 1st generation

Activity in Rituxan refractory patients


Shorter infusions than all other anti-CD20s (1-1.5 v 3-4 hours)




Early Clinical Data for Umbralisib and U2 in CLL Support Successful Phase 3

85% ORR Umbralisib monotherapy (at higher doses)

(Published in Lancet Oncology February 2018)






Mato A, et. al, EHA 2016

CLL is One of the Fastest Growing Global Hematology Markets

- ~115,000 Americans living with CLL
- ~20,000 newly-diagnosed patients each year
- ~20,000 previously treated patients seeking treatment each year





CLL remains incurable despite new treatment options

- Chemo-immunotherapy: nonspecific, toxic contraindicated in certain unfit elderly patients
- BTK inhibitors: tolerability issues can be significant
- PI3K delta inhibitors: tolerability prevents widespread utilization; idelalisib contraindicated in first line therapy
- BCL2 inhibitors: potential for severe tumor lysis syndrome requires enhanced monitoring and hospitalization in many cases



15


- 50,000+ patients treated in the US
- 135,000 patients treated WW

Need for additional highly active, well-tolerated treatments for CLL TG Therapeutics

U2 Offers a Needed Novel Treatment Option for CLL Alternative to or Complementary with Standard of Care

	Community-based Practices (~85%* of Care) ¹	Academic-based Practices (~15% of Care) ¹
BTK Naïve Patients	 U2 (in poor candidates for BTK) U2+BTK (to enhance efficacy) 	 U2 (in poor candidates for BTK/Ven) U2+BTK (to enhance efficacy) U2+Venetoclax (curative intent)
BTK Treated Patients	 U2 (in patients rel/ref/intolerant to BTK) 	 U2 U2+Venetoclax (curative intent)
¹ Oncology Nursing Society, 2016	*Venetoclax currently has limited utiliz monitoring/safety challenges	zation in the community due to TG Therapeutics 16

B-Cell Platform Provides Next Gen Combo's



Ublituximab + Umbralisib (U2) + Ibrutinib

Response Rate Observed with Triple Therapy

•				
Туре	Pts	CR ⁺	PR	ORR
	(n)	(n)	(n)	n (%)
CLL/SLL	19	6	13	19 (100%)
MZL	2	1	1	2 (100%)
MCL	4	2	2	4 (100%)
FL	5	1	3	4 (80%)
DLBCL	6	-	1	1 (17%)
Total	36	10	20	30 (83%)

<u>Ublituximab + Umbralisib + Pembro</u>

Response Rate Observed with Triple Therapy

Group	N	CR N (%)	PR N (%)	ORR N (%)
CLL	10	1 (10%)	8 (80%)	9 (90%)
RT	4	2 (50%)	0	2 (50%)

Mato, et al. ASH 2018

Nastoupil et al, Lugano 2017

Ublituximab in Multiple Sclerosis

- ~1M Americans living with MS
- Completed Phase 2
- ECTRIMS 2019:
 - Final Phase 2 efficacy data & long-term safety data
 - First look at ULTIMATE I & II
 Phase 3 study design & patient demographic data




 Fully Enrolled Phase 3 ULTIMATE Trials under Special Protocol Assessment (SPA)



MS – Phase 2 ARR Comparison

Annualized Relapse Rate (ARR) Comparator




Fox et. al., ECTRIMS October 2018 Kappos L et al. Lancet. 2011; 378:1779-1787 Hauser SL et al. NEJM. 2017; 376:221-234



Ublituximab Phase 2: MRI-Gd Enhancing Lesions

T1 Gd Enhancing Lesions Baseline vs. Week 24 & Week 48



 No T1 Gd-enhancing lesions were detected in any subjects at Week 24 or Week 48 (100% reduction; p=0.003)


Subject T1 Gd MRI at Baseline, Week 24 & Week 48



Fox E et al., ECTRIMS 2018

Significant Opportunity for Ublituximab in MS

Estimated Global Sales



Global Prevalence = ~2.3Million


Global Market Size >\$30Billion by 2025

- Current estimated ocrelizumab share: ~12% of total MS market
- Ocrelizumab >\$2 Billion in 2018 annual sales

Source: Datamonitor 2018 MS Report Prevalence Estimate: Nat'l MS Society Roche JPM 2018 Corporate Update



Multiple Treatment Options Coexist & Account for Meaningful Market Share




Source: Evaluate Pharma, Wall Street Research

Ublituximab Value Proposition in MS

- Equal to better activity with comparable safety
- Convenience of 1 hour infusion every 6 months v.
 3-4 hours for Ocrelizumab
- Strategically priced to optimize patient access
- Estimate \$1-2B annual market opportunity in the US alone for ublituximab in MS



Targeted Key Data & Potential Filings/Approvals 2019-2020



TG Therapeutics 24

Corporate & Financial

Key Financial Statistics

Ticker:	TGTX (NASDAQ)
Price:	\$5.61 (close on 9/30/2019)
Shares:	~94.8M (fully-diluted, as of 8/2/2019)
Cash:	~\$97M (proforma as of 6/30/19)





NASDAQ: TGTX